CAR T Cell Therapy–Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?

CD19-specific chimeric antigen receptor (CAR) T cell therapies have shown remarkable early success in highly refractory and relapsing hematological malignancies. However, this potent therapy is accompanied by significant toxicity. Cytokine release syndrome and neurotoxicity are the most widely repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosh, Arjun K., Chen, Daniel H., Guha, Avirup, Mackenzie, Strachan, Walker, J. Malcolm, Roddie, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Primers in Cardio-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352125/
https://www.ncbi.nlm.nih.gov/pubmed/34396213
http://dx.doi.org/10.1016/j.jaccao.2020.02.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352125/
https://www.ncbi.nlm.nih.gov/pubmed/34396213
http://dx.doi.org/10.1016/j.jaccao.2020.02.011

Ejemplares similares